Sarepta Therapeutics Files 8-K on Equity Sales
Ticker: SRPT · Form: 8-K · Filed: Dec 11, 2025 · CIK: 873303
Sentiment: neutral
Topics: equity-sale, filing, sec
TL;DR
Sarepta sold unregistered equity, check dilution.
AI Summary
On December 10, 2025, Sarepta Therapeutics, Inc. filed an 8-K report detailing unregistered sales of equity securities. The filing also included information on other events and financial statements/exhibits. The company is incorporated in Delaware and its fiscal year ends on December 31st.
Why It Matters
This filing indicates potential new equity issuance by Sarepta Therapeutics, which could impact its capital structure and shareholder dilution.
Risk Assessment
Risk Level: medium — Unregistered equity sales can sometimes signal financial needs or dilution concerns for existing shareholders.
Key Numbers
- 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
Key Players & Entities
- Sarepta Therapeutics, Inc. (company) — Registrant
- December 10, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-14895 (other) — Commission File Number
- 93-0797222 (other) — IRS Employer Identification No.
FAQ
What type of equity securities were sold?
The filing indicates 'Unregistered Sales of Equity Securities' but does not specify the exact type in the provided text.
Were these sales to accredited investors?
The filing mentions 'Unregistered Sales of Equity Securities,' which typically implies sales made under an exemption from registration, often to accredited investors, but specific details are not in the provided text.
What is the purpose of these unregistered equity sales?
The provided text does not state the purpose of the unregistered equity sales.
When was the earliest event reported in this 8-K?
The earliest event reported was on December 10, 2025.
What is Sarepta Therapeutics' Standard Industrial Classification?
Sarepta Therapeutics' Standard Industrial Classification is 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Stats: 1,195 words · 5 min read · ~4 pages · Grade level 12.6 · Accepted 2025-12-11 07:13:42
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share SRPT NASDAQ Glo
- $291.4 million — exchange with the Company approximately $291.4 million in aggregate principal amount of Existi
- $1,000 — Convertible Notes"), which is equal to $1,000 of New Convertible Notes per $1,000 pri
- $31.6 million — and (ii) an aggregate of approximately $31.6 million in cash, which is equal to approximatel
- $108.50 — n cash, which is equal to approximately $108.50 per $1,000 principal amount of Existing
- $120 — unt of Existing Convertible Notes, plus $120.17, less deemed accrued and unpaid inte
- $602 million — of the same series as the approximately $602 million of 4.875% Convertible Senior Notes due
- $893.4 million — rtible Senior Notes due 2030 will total $893.4 million. The foregoing description of the New
Filing Documents
- d55628d8k.htm (8-K) — 31KB
- d55628dex991.htm (EX-99.1) — 10KB
- g55628g1211100042834.jpg (GRAPHIC) — 6KB
- 0001193125-25-315032.txt ( ) — 163KB
- srpt-20251210.xsd (EX-101.SCH) — 3KB
- srpt-20251210_lab.xml (EX-101.LAB) — 17KB
- srpt-20251210_pre.xml (EX-101.PRE) — 11KB
- d55628d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements about the completion of the proposed Exchange. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include, without limitation, satisfaction of customary closing conditions related to the proposed Exchange and that the Company may not be able to consummate the Exchange on the terms described herein. In addition, applicable risks also include those that are listed under the heading "Risk Factors" and elsewhere in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, and in the Company's subsequent filings with the Securities and Exchange Commission. Except as otherwise noted, these forward-looking statements speak only as of the date of this Form 8-K. All forward-looking statements are qualified in their entirety by this cautionary statement. Item9.01
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 99.1 Press Release dated December 11, 2025 104 The cover page from this Current Report on Form 8-K of Sarepta Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit 101
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sarepta Therapeutics, Inc. Date: December 11, 2025 By: /s/ Ian Estepan Ian Estepan President and Chief Operating Officer